Acute effects of sldenafil ctrate (Viagra®) on intraocular pressure in open-angle glaucoma

Grunwald, Juan E.; Jacob, Sindhu S; Siu, Kelly; Piltz, Jody R.; DuPont, Joan

doi:10.1016/s0002-9394(01)01268-5

Cited by 29 publications

(20 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When investigating the effect of sildenafil on IOP in animal models, Gerometta et al realized that a single dose of 50–100 mg sildenafil, along with 20 mg tadalafil increased IOP (14). The results of this study were consistent with other studies but, Grunwald et al concluded that a maximum single-dose use of sildenafil had no significant effect on IOP of patients with chronic open-angle glaucoma (15). Ermis et al also demonstrated that no significant changes were observed in IOP and ocular status after a single-dose use of 50–100 mg sildenafil (16).…”

Section: Discussionsupporting

confidence: 92%

Effect of periodic sildenafil dosage on intraocular pressure in patients with erectile dysfunction

Nazari¹,

Tabrizi²,

Mokhtaree³

2017

Electron Physician

View full text Add to dashboard Cite

Background and aimSildenafil is used to treat erectile dysfunction but it has association with some side effects. This study was conducted with the aim of investigating the effect of duration of taking sildenafil on intraocular pressure (IOP) in patients with erectile dysfunction.MethodsThe study population of this cross-sectional study were all males with erectile dysfunction referring to the urology clinic affiliated to Rafsanjan University of Medical Sciences (Kerman, Iran) over a one-year period (2015–2016) among whom 110 patients were included in the study. After medical examinations and required investigations, a weekly dose of 25–100mg sildenafil (50 mg per week on average) was prescribed for patients. IOP in these patients was measured by an ophthalmologist before, one month after and three months after taking medication respectively. Finally, data were analyzed by SPSS version 16 using repeated measures test.ResultsMean IOP before taking medication as well as one month and three months after taking sildenafil was 14.88±1.3, 15±1.28 and 15±1.34 mmHg respectively. Analysis of results showed that the difference in IOP in various periods of measurement was significant (p<0.001). Mean IOP before taking sildenafil was significantly different from three months after taking it (p<0.001) and mean IOP one month after taking sildenafil was significantly different from three months after taking it (p=0.002).ConclusionResults of this study indicated that taking sildenafil for three months increased IOP. Although these changes may not be clinically significant.

show abstract

Section: Discussionsupporting

confidence: 92%

Effect of periodic sildenafil dosage on intraocular pressure in patients with erectile dysfunction

Nazari¹,

Tabrizi²,

Mokhtaree³

2017

Electron Physician

View full text Add to dashboard Cite

show abstract

“…27 Grunwald and coworkers reported that sildenafil had no harmful effects on IOP in patients with glaucoma. 28 Similarly, we found that vardenafil had no effect on IOP after a short-term administration. However, future studies are needed for long-term results and in patients with preexisting eye disorders.…”

Section: Effects Of Vardenafil On Ocular Hemodynamics 277supporting

confidence: 52%

Effects of Vardenafil on Intraocular Pressure and Orbital Hemodynamics

Taner

Başar²,

Ünal³

et al. 2007

Journal of Ocular Pharmacology and Therapeutics

View full text Add to dashboard Cite

show abstract

“…Pilot studies testing the ability of the PDE5 inhibitor sildenafil to lower IOP were not successful. A single oral dose of 50–100 mg sildenafil failed to impact IOP in POAG patients (Grunwald et al, 2001) and healthy volunteers (Vobig et al, 1999; Sponsel et al, 2000), but did increase blood flow in both healthy subjects (Sponsel et al, 2000; Foresta et al, 2008) and patients with systemic vascular dysfunction (Koksal et al, 2005). Also chronic treatment with sildenafil (twice per week for 3 months) failed to impact IOP (Dundar et al, 2006).…”

Section: The No-cgmp Pathway As a Therapeutic Target For Poagmentioning

confidence: 99%

Regulation of intraocular pressure by soluble and membrane guanylate cyclases and their role in glaucoma

Buys

Potter

Pasquale

et al. 2014

Front. Mol. Neurosci.

View full text Add to dashboard Cite

Glaucoma is a progressive optic neuropathy characterized by visual field defects that ultimately lead to irreversible blindness (Alward, 2000; Anderson et al., 2006). By the year 2020, an estimated 80 million people will have glaucoma, 11 million of which will be bilaterally blind. Primary open-angle glaucoma (POAG) is the most common type of glaucoma. Elevated intraocular pressure (IOP) is currently the only risk factor amenable to treatment. How IOP is regulated and can be modulated remains a topic of active investigation. Available therapies, mostly geared toward lowering IOP, offer incomplete protection, and POAG often goes undetected until irreparable damage has been done, highlighting the need for novel therapeutic approaches, drug targets, and biomarkers (Heijl et al., 2002; Quigley, 2011). In this review, the role of soluble (nitric oxide (NO)-activated) and membrane-bound, natriuretic peptide (NP)-activated guanylate cyclases that generate the secondary signaling molecule cyclic guanosine monophosphate (cGMP) in the regulation of IOP and in the pathophysiology of POAG will be discussed.

show abstract

Acute effects of sldenafil ctrate (Viagra®) on intraocular pressure in open-angle glaucoma

Cited by 29 publications

References 6 publications

Effect of periodic sildenafil dosage on intraocular pressure in patients with erectile dysfunction

Effect of periodic sildenafil dosage on intraocular pressure in patients with erectile dysfunction

Effects of Vardenafil on Intraocular Pressure and Orbital Hemodynamics

Regulation of intraocular pressure by soluble and membrane guanylate cyclases and their role in glaucoma

Contact Info

Product

Resources

About